Navigation Links
Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
Date:1/25/2008

NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KgaA, and Merz Pharmaceuticals GmbH announced that they have filed a second lawsuit in the U.S. District Court for the District of Delaware against additional companies for infringement of U.S. Patent No. 5,061,703 (the '703 patent), which relates to Forest's Namenda(R) product. The defendants named in the lawsuit include Dr. Reddy's Laboratories Limited, Genpharm Inc., Interpharm Inc., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Limited, Sun India Pharmaceutical Industries Limited, and related companies and subsidiaries thereof. The '703 patent expires in April 2010. Forest has applied for patent term extension which, if granted, would extend the '703 patent until September 2013.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

As previously reported, Forest and Merz had received notification from several companies that they had filed Abbreviated New Drug Applications with Paragraph IV certifications to obtain approval to market generic versions of Namenda and commenced an action in patent infringement in the U.S. District Court in Delaware against such filers.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
2. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
3. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
4. Nanotube forests grown on silicon chips for future computers, electronics
5. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
6. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
7. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
9. Octapharma Joins Biotechnology Industry Organization
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 31, 2016 BioRap Technologies Ltd ... Biomedical Research at the Technion - Israel Institute of Technology, ... with Pfizer Inc. (NYSE: PFE ) that aims ... treatment options for a number of chronic autoimmune diseases. ... by Prof. Nathan Karin and his research team, ...
(Date:5/31/2016)... MB (PRWEB) , ... May 31, 2016 , ... ... develops and markets molecular imaging systems, today announced that their compact PET scanner ... (Magnetic Resonance Imaging) has been selected by the University of Arizona (UA). , ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Weeks after hosting ... in Phoenix, Dr. Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, ... The Wrist MRI machine is a state-of-the-art technology and only 1 of about 3 ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):